GSK: welcomes Florida court ruling on Zantac
(CercleFinance.com) - GSK has announced its satisfaction with the Florida court's decision in a case involving Zantac (ranitidine), which excluded the plaintiffs' expert testimony, deeming it 'unreliable'.
As a result, GSK intends to seek dismissal of the Wilson case, in which the plaintiffs allege a link between ranitidine and prostate cancer.
This decision echoes a similar ruling in 2022, which rejected all evidence in federal cases concerning other types of cancer.
Since 2019, scientific studies have found no reliable evidence that ranitidine increases the risk of cancer.
GSK continues to defend itself against the remaining claims.
Copyright (c) 2024 CercleFinance.com. All rights reserved.
As a result, GSK intends to seek dismissal of the Wilson case, in which the plaintiffs allege a link between ranitidine and prostate cancer.
This decision echoes a similar ruling in 2022, which rejected all evidence in federal cases concerning other types of cancer.
Since 2019, scientific studies have found no reliable evidence that ranitidine increases the risk of cancer.
GSK continues to defend itself against the remaining claims.
Copyright (c) 2024 CercleFinance.com. All rights reserved.